Status
Completed
Phase
Phase 3
Enrollment
315
Locations
1
Results
Not posted
Publications
0
Study summary
The study aims is to verify the hypothetize that inhaled Tranexamic Acid (TXA) or Terlipressin (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. This randomized double-blind multicenter triple arm trial compares the administration of TXA to TER to placebo in patients with mild to severe hemoptysis.
In over 90% of cases, hemoptysis is due to a bronchial or non-bronchial systemic arterial mechanism. Embolization of Bronchial Arteries (EBA) is the main specific treatment but is not easily available. Medical treatment for hemoptysis is not evidence-based. For this study, the investigators will dispense trial drugs using inhalation route which has not been evaluated in mild to severe hemoptysis in previous trials. In addition, as opposed to previous trials, the investigators will assess the safety of trials drugs during hospital stay. Acid tranexamic (TXA), an antifibrinolytic drug, reduces bleeding in uterine and traumatic haemorrhage by blocking the action of plasmin on fibrin. Intravenous terlipressin (TER), a vasoconstrictor, contributes to control digestive haemorrhage but presents many contraindication when administrated by intravenous route. The investigator hypothetize that inhaled antifibrinolytic (TXA) or vasoconstrictor (TER) will be associated with an increase in the rapid control of hemoptysis without side-effects. Patients will be randomized into 3 groups: * Active treatment 1: Tranexamic Acid 500 mg three times a day (every 8 hours) for 3 days. * Active treatment 2: Terlipressin 1 mg three times a day (every 8 hours) for 3 days. * Placebo: normal saline nebulization three times a day (every 8 hours) for 3 days. Using a hierarchical analysis, the comparison between TXA and TER will be tested once superiority on efficacy of both inhaled TXA and TER vs placebo is demonstrated. The above secondary objectives will then be assessed for the comparison of TXA versus TER.
Interventions
DRUG
Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 500 mg x 3/day (= 500 mg / 8 hours) Treatments duration: 3 days
DRUG
Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 1 mg x 3/day (= 1 mg / 8 hours) Treatments duration: 3 days
DRUG
Jet nebulization (a device connected by tubing to compressed air or oxygen to flow at high velocity through a liquid medicine to turn it into an aerosol, which is then inhaled by the patient). The nebulization lasts 10 minutes. Posology: 5ml x 3/day (= 5 ml / 8 hours) Treatments duration: 3 days.
Timeline
First posted
Jul 14, 2021
Study start
Mar 27, 2022
Primary completion
Dec 28, 2025
Study completion
Mar 25, 2026
Results posted
Not reported
Registry updated
Apr 23, 2026
Outcomes
Number of patients with complete or partial resolution of hemoptysis without the use of any interventional procedure.
Time frame · 3 days
Efficacy of inhaled tranexamic acid and inhaled terlipressin versus placebo (normal saline) in immediate control of mild to severe hemoptysis within the first 3 days of hospitalization. A complete resolution of hemoptysis is defined by absence of recurrence within 3 days; partial resolution is defined as hemoptysis recurrence \< 50 ml within the first 3 days
Rate of complete resolution of hemoptysis within 3 days, as previously defined
Time frame · 3 days
Complete resolution of hemoptysis, as previously defined
Rate of partial resolution of hemoptysis defined as recurrence < 50 ml
Time frame · 3 days
Partial resolution of hemoptysis, as previously defined
Rate of patients with total volume of hemoptysis < 200 ml
Time frame · 3 days
Total volume of hemoptysis \< 200 ml
Rate of patients who need an endovascular treatment (bronchial arterial endovascular embolization)
Time frame · 3 days
Need of invasive procedure such as bronchial arterial endovascular embolization
Time between hospital admission and bronchial arterial endovascular embolization
Time frame · 3 days
Time between hospital admission and endovascular treatment
Rate of patients who need a mechanical ventilation
Time frame · 3 days
Need of invasive procedure such as mechanical ventilation,
Rate of specific adverse events
Time frame · 3 days
Specific Adverse Events (AE) : acute myocardial ischemia, symptomatic venous thromboembolism, hyponatremia (\<130 mmol/L), bronchospasm (defined by the need of short-acting bronchodilatator).
Rate of in-hospital mortality
Time frame · 30 days
Rate of patients with hemoptysis recurrence
Time frame · 30 days
Death rate
Time frame · 30 days
Eligibility
Inclusion Criteria: * Patients over 18 years, under 90 years * Mild to severe hemoptysis that has been going on for less than 7 days * Total expectorate blood ranging from 50 ml to 200 ml * Admission in emergency department or ICU for less than 12 hours * Social security affiliation * Signed informed consent * For child-bearing aged women, efficient contraception includes oral oestrogen- progestin, oral progestin, progestin implants and all types of intrauterine devices Exclusion Criteria: * Need for mechanical ventilation * Cystic fibrosis * Pregnancy or breast feeding * Contraindication for contrast agents injection (renal failure with creatinin clearance \< 30mL/min, know allergy to contrast agents injection) * Known hypersensitivity to TXA or TER or one of its excipients * Know previous cardiac arrhythmia (atrial fibrillation, atrial flutter..) * Contraindication to TXA (including renal failure with creatinin clearance \< 30mL/min) or TER therapy : * acute myocardial infarction in the 6 past months, * intrathecal injection in the 3 past months, * seizure in the past 3 months * Participation in another interventional study or being in the exclusion period at the end of a previous study. * Patient under tutorship or / guardianship, and incapable to give informed consent
Study locations
France. Showing up to 24 locations stored in the fast local snapshot.
AP-HP, Hôpital Européen Georges Pompidou
Paris, France
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Montefiore Medical Center · Cervical Preparation
Phase 1
Recruiting
94
2026-07
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremias · Water Intoxication
Phase 3
Completed
205
2026-07
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremia
Phase 3
Completed
243
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.